Cell kinetic measurements: Principles, guidelines for treatment?

Hepato-Gastroenterology

Volumn 46, Issue 26, 1999, Pages 670-678

  Haustermans, K ^a,b   Fowler, J ^a   Geboes, K ^a   Lerut, A ^a   Van Cutsem, E ^a   Begg, A ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Flow cytometry; IUdR; Tumor cell kinetics

Indexed keywords

CYTOSTATIC AGENT;

ARTICLE; BIOPSY; CELL KINETICS; CELL PROLIFERATION; CYTOMETRY; FLOW CYTOMETRY; HUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

BIOPSY; CARDIA; CELL CYCLE; CELL DEATH; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DIGESTIVE SYSTEM; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; GASTROINTESTINAL NEOPLASMS; HUMANS; IDOXURIDINE; MATHEMATICAL COMPUTING; PRACTICE GUIDELINES; PROGNOSIS; STOMACH NEOPLASMS;

EID: 0032905931     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. 1 Silvestrini R, Daidone MG, Valagussa P, et al: Thymidine labeling index as a prognostic indicator in node positive breast cancer. J Clin Oncol 1990; 8:1321-1326.
2. 2 Begg AC, Hofland I, Van Glabbeke M, Bartelink H, Horiot JC: Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin Radiat Oncol 1992; 1:22-25.
3. 3 Bourhis J, Dendale R, Hill C, Bosq J, Janot F, Attal P, Fortin A, Marandas P, Schwaab G, Wibault P, Malaise EP, Bobin S, Luboinsky B, Eschwege F, Wilson G: Potential doubling time in head and neck squamous cell carcinoma treated with 70 Gy in 7 weeks. Int J Radiat Oncol Biol Phys 1996; 35(3):633-634.
4. 4 Corvo R, Giaretti W, Sanguineti G, Geido E, Orecchia R, Guenzi M, Margarino G, Bacigalupa A, Garaventa G, Barbieri M, Vitale V: In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol 1995; 13:1843-1850.
5. 5 Awwad HK, Khafagy Y, Barsoum M, Ezzat M, El-Attar I, Farag H: Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumor proliferation. Radiother Oncol 1992; 25:261-266.
6. 6 Gregory WM: Cell proliferation and the principles of cancer therapy. In: Hall PA, Levison DA, Wright NA (Eds.). Assessment of cell proliferation in clinical practice. Springer-Verlag, 1992; pp. 193-205.
7. 7 Nishimura Y, Ono K, Tsutsui K, Oya N, Okajima K, Hiraoka M, Abe M: Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. Int J Radiation Oncology Biol Phys 1994; 30:1099-1105.
8. 8 Fowler JF: How worthwhile are short schedules in radiotherapy? A series of exploratory calculations. Radiother Oncol 1990; 18:165-181.
9. 9 Fowler JF: The phantom of tumor treatment - continually rapid proliferation unmasked. Radiother Oncol 1991; 22:156-158.
10. 10 Peters LJ, Brock AW, Chapman JD, Wilson G: Predictive assays of tumor radiocurability. Am J Clin Oncol 1988; 11:275-287.
11. 11 Steel GG: Growth kinetics of tumours. Oxford University press, 1977.
12. 12 Tubiana MLH: Gray medal lecture: cell kinetics and radiation oncology. Int J Radiat Oncol Biol Phys 1982; 8:1471-1489.
13. 13 Mendelsohn ML: Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. III. The growth fraction. J Natl Cancer Inst 1962; 28:1015-1029.
14. 14 Gratzner HG: Monoclonal antibody to 5-bromo-and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 1982; 218:474-475.
15. 15 Dolbeare F, Gratzner HG, Pallavicini MG, Gray J: Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 1983; 80:5573-5577.
16. 16 Begg AC, Mc Nally NJ, Schrieve DC, Karcher H: A method to measure the duration of DNA synthesis and the Potential doubling time from a single sample. Cytometry 1985, 6:620-626.
17. 17 Withers HR, Taylor JMG, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131-146.
18. 18 Fowler JF: Potential for increasing the differential response between tumors and normal tissues: can proliferation be used? Int J Radiat Oncol Biol Phys 1986; 12:641-645.
19. 19 Begg AC, Hofland I: Cell kinetic analysis of mixed populations using three-color fluorescence flow cytometry. Cytometry 1991; 12:445-454.
20. 20 Peto R, Pike MC, Armitage P, Breslaw NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Brit J Cancer 1977; 35:1-39.
21. 21 Haustermans K, Vanuytsel L, Geboes K, Lerut T, Van Thillo J, Leysen J, Cosemans W, van der Schueren E: In vivo cell kinetic measurements in human esophageal cancer: what can be learned from multiple biopsies? European Journal of Cancer 1994; 12(30A):1787-1791.
22. 22 Haustermans K, Hofland I, Pottie G, Ramackers M, Begg AC: Can measurements of potential doubling time (Tpot) be compared between laboratories? A quality control study. Cytometry 1995; 2(19):154-163.
23. 23 Haustermans K, Fowler J, Geboes K, Christiaens M, Lerut A, van der Schueren E: Relationship between potential doubling time (Tpot), Labeling index and duration of DNA synthesis in 60 esophageal tumors and 35 breast tumors. Is it worthwhile to measure Tpot? Radiotherapy and Oncology 1998; 46:157-168.
24. 24 Haustermans K, Hofland I, Ivangi D, Balen AMJ, Geboes K, Lerut T, Fowler J, van der Schueren E, Begg AC: Flow cytometric analysis of biopsies containing tumor and normal cells using gating on cytokeratin. Radiotherapy and Oncology 1996; 41:237-248.
25. 25 Haustermans K, Geboes K, Lerut A, Fowler J, van der Schueren E: Disease free survival and local control as a function of Tpot, LI and Ts. European Journal of Surgical Oncology 1997; 23:293-297.